Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 9/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380160 | 0.83 | HTT (0.49) | THRB | |
| SCHEMBL5383096 | 0.82 | AR (0.46) | ARGRM4KDRBRAFNPY5R | |
| SCHEMBL5370304 | 0.82 | EPHX2 (0.46) | THRB | |
| SCHEMBL5374672 | 0.81 | AR (0.42) | ARCXCR3GRM4KDRBRAF | |
| SCHEMBL5380110 | 0.81 | AR (0.42) | ARCXCR3GRM4KDRBRAF | |
| SCHEMBL5371543 | 0.81 | AR (0.42) | ARCXCR3GRM4KDRBRAF | |
| SCHEMBL5378499 | 0.81 | KMT2A (0.45) | — | |
| SCHEMBL5379010 | 0.80 | LMNA (0.53) | UBE2MDCUN1D1 | |
| SCHEMBL5371602 | 0.77 | RAB9A (0.46) | — | |
| SCHEMBL5374201 | 0.77 | EPHX2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179943-B2 | Bicyclic derivatives that modulate voltage-gated potassium channels and methods of use thereof | WYETH (US) | 2007-02-20 | — | — | US | claimed |
| US-20060004108-A1 | Bicyclic derivatives that modulate voltage-gated potassium channels and methods of use thereof | WYETH (US) | 2006-01-05 | — | — | US | claimed |
| US-7179943-B2 | Bicyclic derivatives that modulate voltage-gated potassium channels and methods of use thereof | WYETH (US) | 2007-02-20 | — | — | US | disclosed |
| US-20060004108-A1 | Bicyclic derivatives that modulate voltage-gated potassium channels and methods of use thereof | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004108-A1 | Bicyclic derivatives that modulate voltage-gated potassium channels and methods of use thereof | KCNAB1, KCNA1, KCNN1 | AR 3664/4885CXCR3 3470/4885GRM4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.